1. Pink Sheet
  2. >>Archive

Pfizer Moves CNS And Cardio-Metabolic Research To Cambridge, Mass., Promotes Cross-Talk With Local Scientists

 
• By Michael Goodman

Pfizer has relocated its neuroscience and cardiovascular medicine research groups from Groton, Conn., to Cambridge, Mass. Currently in temporary labs, the research will move into permanent space in 2013. The goal is to foster cross-talk and collaboration with local scientists and with Pfizer’s CTI program in nearby Boston.

Pfizer Inc. is in the midst of moving its cardiovascular and neuroscience research units from Groton, Conn., to Cambridge, Mass., with a goal of completing the relocation fully next year. It’s a process that began in February 2011, when the pharma first announced plans to move the two divisions; in September 2011, it signed a lease with Massachusetts Institute of Technology, giving it 180,000 square feet of newly constructed lab and office space in Cambridge’s Kendall Square.

The new building, at 610 Main Street, is scheduled for completion in the fourth quarter of 2013. In the meantime,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 
• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 
• By Francesca Bruce

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

EU Pharma Reform: Council Proposal A ‘Step In The Right Direction’ But ‘More Work To Be Done’

 
• By Eliza Slawther

Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.